"Tergene Biotech develops vaccine to combat pneumonia", 16 Jul 2015

An Indian biotech start up [Tergene Biotech] has developed a promising candidate vaccine to combat pneumonia…At present the global market, estimated to be $5 billion is dominated by three multinationals…Tergene is deploying novel vaccine technology to cut time and cost and make the vaccine affordable. At the current price of close to $60 (Rs 3,500 per dose. Course is three doses) the vaccine is inaccessible to most of the population in India and other Asian/African where disease burden is highest and is the largest cause of death of children…[Also refers to Aurobindo Pharma, Panacea Biotech, Serum Institute]